14 Result(s)
within
Donna P. Ankerst
Urology
-
Chapter
Pitfalls in Prostate Cancer Biomarker Evaluation Studies
Biomarker studies in prostate cancer research aim to discover new markers or novel uses of prostate-specific antigen (PSA) to complement or replace PSA as the existing standard for screening. These studies oft...
-
Chapter
Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator
The Prostate Cancer Prevention Trial (PCPT) Prostate Cancer Risk Calculator provides a single probability of prostate cancer and of high-grade disease (Gleason grade
-
Chapter
Statistical Evaluation of Markers and Risk Tools for Prostate Cancer Classification and Prediction
Adopting novel biomarkers for use in prostate cancer screening requires rigorous scientific evaluation. The predictive accuracy of the markers must be quantified and compared with other potential markers. In t...
-
Chapter
The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening
When considering the application of a screening test for any disease, it is extremely important to understand how the performance characteristics of a test will affect its usefulness to a patient as well as to...
-
Article
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group
To evaluate the discrimination, calibration, and net benefit performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) across five European randomized study of screening for prostate cancer ...
-
Article
Editorial for special issue on epidemiology and prevention of prostate cancer
-
Article
Prostate cancer incidence and survival in immigrants to Sweden
The large international variation in the incidence of prostate cancer (PC) is well known but the underlying reasons are not understood. We want to compare PC incidence and survival among immigrants to Sweden i...
-
Article
Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group
To assess the applicability of the Prostate Cancer Prevention Trial High Grade (Gleason grade ≥ 7) Risk Calculator (PCPTHG) in ten international cohorts, representing a range of populations.
-
Article
Open AccessA case control study of sarcosine as an early prostate cancer detection biomarker
Sarcosine has been investigated as a prostate cancer biomarker with mixed results concerning its predictive power. We performed a case–control evaluation of the predictive value of serum sarcosine for early de...
-
Article
Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy
We aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP).
-
Article
Open AccessNo detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance
To assess whether a first-degree family history or a fatal family history of prostate cancer (PCa) are associated with postoperative upgrading and upstaging among men with low risk and favourable intermediate-...
-
Article
Open AccessLong-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
The safety of active surveillance (AS) in favorable intermediate-risk (FIR) prostate cancer (PCa) remains uncertain. To provide guidance on clinical decision-making, we examined long-term and pathological outc...
-
Article
Open AccessPrevalence and determinants of decision regret in long-term prostate cancer survivors following radical prostatectomy
Patients with localized prostate cancer (PC) are faced with a wide spectrum of therapeutic options at initial diagnosis. Following radical prostatectomy (RP), PC patients may experience regret regarding their ...
-
Article
Open AccessPredicting clinically significant prostate cancer following suspicious mpMRI: analyses from a high-volume center
mpMRI is routinely used to stratify the risk of clinically significant prostate cancer (csPCa) in men with elevated PSA values before biopsy. This study aimed to calculate a multivariable risk model incorporat...
